Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
ATR [12]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM 1.8 μM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXwRnR7Oi53IN88US=> MXexMVQh\A>? M3jrUWROW09? NX;UUHRk\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MW[yOVQ6ODN6Mx?=
H1703 NGTBUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLw[ZYzNjVizszN MlW5NU01KGR? M3i1dGROW09? NYq0[lVL\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? NWPndlhTOjV2OUCzPFM>
HUVECs NHjPTlJEgXSxdH;4bYNqfHliQYPzZZk> M{n2TlExOCCwTR?= NGXXOY4zPCCq MnG3ZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NXPIWoZJOjV2NUCxPFY>
APRE-19 M3zWNmFxd3C2b4Ppd{BCe3OjeR?= NIOwT4U2KM7:TR?= NEnUdXgzPCCq MmXEZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? MojVNlU{Ojl4MUe=
MDA-MB-231 NIXKfpJCeG:ydH;zbZMhSXO|YYm= MXqxxsDPxE4EoB?= NGDpUmg1QCCq M1XjO2ROW09? MX3k[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= M1nxO|I2OzByOUOy
MCF7 NEPufHdHfW6ldHnvckBCe3OjeR?= MlXZNVAxKG6P M1Sxb|I1KGh? NFv2cXhmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? M2LrVVI2OTd{NUW3
HT-29  M{T3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnnUWI2OS53wrFCuW0> MkLlPVYhcA>? NF\BTVdl\WO{ZXHz[ZMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIlvcGmkaYTl[EBjgSCNWV7B NH65fmMzPTBzMkGyNy=>
MO59K  NGq0dlREgXSxdH;4bYNqfHliQYPzZZk> NWTWbmRuPcLizszN NIH5eXE4KGR? MVrEUXNQ NIi1O|VmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= M{PNR|I1QTV|NU[x
MO59J NEDLdHFEgXSxdH;4bYNqfHliQYPzZZk> M1vROlXDqM7:TR?= NWPYZ|VnPyCm NFnJfG9FVVOR NVrpSoV3\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu NEfhdogzPDl3M{W2NS=>
MO59K  MWrBdI9xfG:|aYOgRZN{[Xl? MnnONVAh|ryP NXPqdFFtOjRiaB?= NULiN2NHTE2VTx?= MVHpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> NFKzTZYzPDl3M{W2NS=>
MO59J NIDibotCeG:ydH;zbZMhSXO|YYm= MWqxNEDPxE1? NH;R[VYzPCCq M4m2bGROW09? MY\pcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> M1\sSFI1QTV|NU[x
HepG2 NYrXbnBRTnWwY4Tpc44hSXO|YYm= MmjNNVAxKG6P NVPIR41oOC53IHi= MWLEUXNQ MVnicI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u NFX4dlEzPDh4M{O1NC=>
A549  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO0N{DDvU4EoB?= MYSyJIg> NYPOUoxre3WycILld5NmeyCyZX3leJJmgGWmLXnu[JVk\WRiQXv0JIFv\CCJU1uz{tIh[WO2aY\heIlwdixiUz3wbIF{\SCjcoLld5QtKGOnbHygZZBweHSxc3nzJIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbh?= MUGyOFg1Pzh4Mx?=
A549  MmXXSpVv[3Srb36gRZN{[Xl? MkfUNVDDqM7:bdMg NH21dpIyPiCq MXzEUXNQ M37NR41w\HWuYYTld{B1cGViSVHWJJJmeGyrY3H0bY9vKGGwZDDjZZV{\XNicnX0[Y51cW:wIH;mJG5RKGmwIITo[UBvfWOuZYXzMi=> MU[yOFgxOjFzMR?=
SK-N-LO NULIdoJ{TnWwY4Tpc44hSXO|YYm= NYjIfYF[OTByIH7N MXGwMlUhcA>? NWL5dm5q\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w Mm\NNlQ3PTR4ME[=
HL-60 NGD0bo5HfW6ldHnvckBCe3OjeR?= MV[wMlHDqM7:TR?= M1TLXFczKGh? NHjK[ZpjdG:la4Og[IF{[XSrbnniMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44> MkPSNlQ3ODd{N{O=
HepG2  MY\GeY5kfGmxbjDBd5NigQ>? MnfLNlAxKG6P MYiwMlUhcA>? NEXOR|lifHSnboXheIV{KE[xeF:gdIhwe3Cqb4L5cIF1cW:w NVfWfXNmOjR3M{WxPVI>
H520 NEXVNHBHfW6ldHnvckBCe3OjeR?= NX\KSGc1OTEEoN88US=> NVnKNVI2OSCq MlTrSG1UVw>? MYTk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NXrZeJBTOjR2NEe5N|U>
H1975 M1n1[WZ2dmO2aX;uJGF{e2G7 NIDHVVUyOMLizszN MXOxJIg> NUPjOZV2TE2VTx?= NH:5RVJl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> MVqyOFQ1Pzl|NR?=
MG-63 M1iwPWFxd3C2b4Ppd{BCe3OjeR?= MnS4NVAhyrWP Ml\LNVIhcA>? NYjGVHJz\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NEDSe2MzPDN3OEOwNS=>
5637 NEnzN5BCeG:ydH;zbZMhSXO|YYm= MWSxNOKh|ryP MonKOFAhdWmw NGrESlBz\X[ncoPld{BxOjGZQV[xJIV5eHKnc4Ppc44tKEOGSzDlfJBz\XO|aX;uMEBidmRiY3XscEBqdmirYnn0bY9vKGmwZIXj[YQh[nliZoXjc4ll[W5? MkXxNlQ{OzN6Nki=
HEK-293 NGe1UGhHfW6ldHnvckBCe3OjeR?= MUWxOVBvVQ>? M3TTfVE3KGh? Ml\TSG1UVw>? NWHXfWRX\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= M2q3e|I1OzJ2M{[2
SW480  NHnmeldHfW6ldHnvckBCe3OjeR?= MUixOVBvVQ>? NEPMT2gzOCCq M1rvRWROW09? MU\y[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw MX6yOFMzPDN4Nh?=
HepG2 NVzu[FM5TnWwY4Tpc44hSXO|YYm= MmHSNVAxKG6P NHPPfXkzPCCq NILuVXdifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= NV7rboV4OjR{OUe1NVA>
HCT 116  M37JWWZ2dmO2aX;uJGF{e2G7 MVOxNFAhdk1? NUfReZBrOjRiaB?= NEfZe|hifHSnboXheIV{KHSqZTDjc4xwdmmnczDv[kB1cGVidIXtc5Ih[2WubIOge4l1cCC3cILl[5Vt[XSrb36gc4YhSWu2MR?= NIS4bnYzPDJ7N{WxNC=>
BEL/FU M3v3SmZ2dmO2aX;uJGF{e2G7 NV[5ZWdZOSCvTR?= MYGyOEBp NH24Oo9l\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? M4TNUlI1OjN{MEm5
Huh7  MXzGeY5kfGmxbjDBd5NigQ>? M{D4elPDqM7:TR?= NUXZUIlpOSCq MXry[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> MXGyOFE5PDF7Nh?=
A-375 NV3VZW1vSXCxcITvd4l{KEG|c3H5 MVq0M|gh|ryP MoX3NlQhcA>? NEDlN4xmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MmnkNlQyOTNzN{O=
A-375-TS  MUjBdI9xfG:|aYOgRZN{[Xl? MUi0M|gh|ryP MlHxNlQhcA>? NFPQVppmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NUXs[I9UOjRzMUOxO|M>
Mel-HO NXOyXm94SXCxcITvd4l{KEG|c3H5 NI\OW5I1NzhizszN MYqyOEBp NYj1T|hz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M2H2XVI1OTF|MUez
Mel-HO-TS MkjnRZBweHSxc3nzJGF{e2G7 NFPVVIk1NzhizszN NXnhdpZROjRiaB?= NH\afYNmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NXW1OGRMOjRzMUOxO|M>
MeWo NXjNTllHSXCxcITvd4l{KEG|c3H5 NHvEfWg1NzhizszN Mn3FNlQhcA>? NF3NUItmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MWWyOFEyOzF5Mx?=
Mel-2a NGfSVJhCeG:ydH;zbZMhSXO|YYm= NHnxT5g1NzhizszN MUiyOEBp NVi1[3pY\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MXuyOFEyOzF5Mx?=
MDA-MB-231 NX;hWVVHTnWwY4Tpc44hSXO|YYm= NXSxWVNvOOLCk{SwNEBvVQ>? MnHkOEBp NXT2N3FWe3WycILld5NmeyCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NX7OTGhpOjJ7ME[yOVk>
MDA-MB-231 NVnkU5h{TnWwY4Tpc44hSXO|YYm= NWL5cohRPDByIH7N MofuOEBp MoDJ[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn;zNlI6ODZ{NUm=
Jurkat MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7n[VlTOC5{NT2xMlI2KM7:TR?= NVjLNox[OjRxNEigbC=> NYnGVVQ6TE2VTx?= NIPWWYFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MYKxPVc2PzF6NR?=
Namalwa NGLyfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMlI2NTFwMkWg{txO MX6yOE81QCCq NHfRToZFVVOR NED4OWtqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= M1Szd|E6PzV5MUi1
Jurkat MmjFRZBweHSxc3nzJGF{e2G7 NIewWm4xNjJ3LUGuNlUh|ryP MXqyOE81QCCq M{XYeWROW09? NEDKVZBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NUHhdWRIOTl5NUexPFU>
Namalwa M1rhdWFxd3C2b4Ppd{BCe3OjeR?= Ml\hNE4zPS1zLkK1JO69VQ>? MX:yOE81QCCq NVHFb3pETE2VTx?= NXTvZpF1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MYexPVc2PzF6NR?=
K562 NYLCZ|FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXRNlQhcA>? M{jvcWlEPTB;MkZCtVAvOTRibl2= MoX1NVk3PjJ|NkG=
SW1990 NIXvT|BHfW6ldHnvckBCe3OjeR?= NEO1V3oxNjBzLUGg{txO NVzTV5JZOSCq MnP2bY5pcWKrdIOgTGEucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v M3r1blE6PDZ7MEKw
RT112  NX;HWVdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLOWZYzOTEEoN88US=> MWiyOEBp NFnjTWlFVVOR M2K5dYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ NUnPV5dsOTh5OEe4N|I>
MHG-U1 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r1bVExyqEQvF2= NVnVW493OjRiaB?= NVTZb3g1TE2VTx?= MXzk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> NX\qT5BSOTh5OEe4N|I>
SMMC-7721 MmPMRZBweHSxc3nzJGF{e2G7 MVmyNFDDqG6P M4LFN|I1KGh? MYPpcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ Ml\GNVc2PTdzOUG=
SMMC-7721 NHzuZ5hHfW6ldHnvckBCe3OjeR?= MlXWNlAxyqCwTR?= M2jTPVI1KGh? NXnES3RMfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= MmnNNVc2PTdzOUG=
HeLa NEjzU2hHfW6ldHnvckBCe3OjeR?= MoLiNVAxyqCwTdMg M1zZPVEhcA>? MYrhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= MWixOlg6ODlzNR?=
MRC5VI M1\Xb2Z2dmO2aX;uJGF{e2G7 MVixNk42KG2P MYOwMlUhcA>? M4LRNGROW09? NFr0coNi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MV6xOlIzPzN7NB?=
AT5BIVA NUfBeVhuTnWwY4Tpc44hSXO|YYm= NWPOcodpOTJwNTDtUS=> NY\lc293OC53IHi= NXS2UlFUTE2VTx?= NV\tTHhs[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? MYKxOlIzPzN7NB?=
M059J NV\BZWNkTnWwY4Tpc44hSXO|YYm= NYrU[4k4OTJwNTDtUS=> NETqTokxNjViaB?= M1fVVWROW09? NFmxdoJi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MnjINVYzOjd|OUS=
HeLa M2DCN2Z2dmO2aX;uJGF{e2G7 M2DGVlEzNjVibV2= NHnL[Y8xNjViaB?= NV\YOIdLTE2VTx?= NYLQfVZv[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NVrUTGZYOTZ{MkezPVQ>
N2a MlXjRZBweHSxc3nzJGF{e2G7 MYKwMlEuOTBizszN NGn6dpMzKGh? NGHx[2lqdmS3Y3XzJIRm[3KnYYPl[EBk\WyuII\pZYJqdGm2eTDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= M3\zcFE2QDR{N{[3
Jurkat  NEH6V5hMcW6jc3WgRZN{[Xl? MlfkTWM2OCCxZjCyOEBvVQ>? NF:0NlAyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5%DMSO+corn oil 11mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID